Costs of diabetes and its complications in Poland
Diabetes mellitus (DM) is a major health problem with severe complications and a significant impact on quality of life. It constitutes an enormous burden of disease due to high prevalence, severe co-morbidities and high costs for society. This study is the first comprehensive study on the direct and indirect costs of DM (type 1 and type 2) and associated complications in Poland.
In order to estimate the direct medical costs of DM and its complications, including the costs of medical consultation, hospitalisation, rehabilitation, drugs and medical equipment, data from the National Health Fund were used. Indirect costs on loss of productivity due to diabetes and its complications were based on data obtained from the ZUS (Social Insurance Institution) and from GUS (Poland’s Central Statistical Office). Attributable risk methodology was used to assess the burden of DM complications.
A continuous increase of the direct costs of diabetes has been observed since the year 2005. In the analysed time period (2005–2009) the direct costs of medical services for both types of DM doubled. DM is a cause of significant sickness absence and incapacity for work and therefore is associated with a growing productivity decline in Poland. The highest direct costs and indirect costs are associated with treatment of diabetes-related complications. Direct costs of hospital complication treatment were EUR 332 million, which exceeded by more than five times the direct costs of hospital treatment of diabetes per se, which in the same year amounted to EUR 58.5 million. The indirect costs of diabetes-related complications were higher by 41 % compared with indirect costs related to DM itself. Total costs of health care services for DM and its complications amounted to EUR 654 million, which constitutes a 2.8 % of total health care costs in Poland. Total DM cost in Poland in 2009 amounted EURO 1.5 billion.
DM is causing a growing economic burden on the health care system and on Polish society in terms of health care and productivity losses. Most of the total cost of diabetes are indirect costs caused by productivity losses. Both direct and indirect costs are driven by the cost of diabetes complications.
- Lundman, B., Engström, L.: DM and its complications in a Swedish county. DM. Res. Clin. Pr. 39(2), 157–164 (1998) CrossRef
- Andel, M., Grzeszczak, W., Michalek, J., Medvescek, M., Norkus, A., Rasa, I., Niewada, M., Kamiski, B., Kraml, P., Madacsy, L.: The DEPAC group: a multinational, multi-centre, observational, cross-sectional survey assessing DM secondary care in Central and Eastern Europe (DEPAC survey). Diabet. Med.J. British Diabet. Assoc. 25(10), 1195–1203 (2008) CrossRef
- Wittek, A., Sokalski, B., Grzeszczak, W., Strojek, K.: Prevalence of DM and cardiovascular risk factors of industrial area in southern Poland. Exp. Clin. Endocrinol. DM 117, 350–353 (2009) CrossRef
- Ballesta, M., Carral, F., Olveira, G., Giron, H.A., Aguilar, M.: Economic costs associated with type II DM in Spanish patients. Eur. J Health Econ. HEPAC Health Econ. Prev. care. 7(4), 270–275 (2006) CrossRef
- Ferber, L., Köster, I., Hauner, H.: Medical costs of diabetic complications, total costs and excess costs by age and type of treatment results of the German CoDiM study. Exp. Clin. Endocrinol. DM Off. J. Ger. Soc. Endocrinol. Ger. DM Assoc. 115(2), 97–104 (2007)
- Hex, N., Bartlett, C., Wright, D., Taylor, M., Varley, D.: Estimating the current and future costs of Type 1 and Type 2 DM in the UK, including direct health costs and indirect societal and productivity costs. Diabet. Med. 29, 855–862 (2012) CrossRef
- Bolin, K., Gip, C., Mork, A.-C., Lindgren, B.: DM, healthcare cost and loss of productivity in Sweden 1987 and 2005—a register-based approach. Diabet. Med. 26, 928–934 (2009) CrossRef
- Kinalska, I., Niewada, M., Głogowski, C., Krzyżanowska, A., Gierczyński, J., Łatek, M., Kamiński, B.: Koszty cukrzycy typu 2 w Polsce (Badanie CODIP). Diabetologia Praktyczna 5(1), 1–8 (2004) CrossRef
- Kawalec, P., Pilc, A.: Analiza kosztów leczenia powikłań cukrzycy poniesionych przez płatnika w Polsce w 2002 roku. Diabetologia Praktyczna 5(1), 9–14 (2004)
- Kawalec, P., Pilc, A.: Koszty pośrednie cukrzycy w Polsce. Diabetologia Praktyczna 7(4), 211–215 (2006)
- Tarricone, R.: Cost-of-illness analysis. What room in health economics? Health Policy 77(1), 51–63 (2006) CrossRef
- American DM Association: Economic cost of DM in the US in 2002. DM Care 26, 917–932 (2003)
- DM Atlas Update 2012: Regional and Country Fact Sheets, IDF 2012
- American DM Association: Economic costs of DM in the U.S. In 2007. DM Care 31(3), 596–615 (2008) CrossRef
- Costs of diabetes and its complications in Poland
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
The European Journal of Health Economics
Volume 15, Issue 6 , pp 653-660
- Cover Date
- Print ISSN
- Online ISSN
- Springer Berlin Heidelberg
- Additional Links
- Diabetes type
- Cost of disease
- Indirect cost
- Industry Sectors
- Author Affiliations
- 1. Koźminski University, 57/59 Jagiellońska St., 03-301, Warsaw, Poland
- 2. Novo Nordisk, 17 stycznia 45 St., 02-146, Warsaw, Poland
- 3. Starowiślna 17/3 St., 31-038, Kraków, Poland